CNS, Neurometabolism, Multiple Sclerosis

MedDay is an international pioneering pharmaceutical company targeting brain metabolism to treat nervous system disorders. Our pipeline includes the lead product MD1003 for primary and secondary progressive multiple sclerosis that has successfully completed phase III clinical trials in 2015 in France and a confirmatory phase III trial SPI2 is ongoing in North America and other European countries with results expected Q1 2020. Other therapeutic targets are pursued with an in-house proprietary state-of-the-art metabolomics platform.
Medday is looking to enlarge the pipeline and portfolio with external assets from discovery to the clinical development stage and is flexible to different types of partnerships with the pharma industry and academia.